A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants

In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.
In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):
Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.
The main questions researchers want to answer are:
* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.
Each participant will be in the study for about 22 weeks.

Start Date02 Jan 2025

Sponsor / Collaborator

Biogen, Inc.

NCT06044337

/ Enrolling by invitationPhase 3

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301.
The main objective of the study is to learn more about the long-term safety of litifilimab.
The main question researchers want to answer is:
* How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are health problems that may or may not be caused by the study drug.
Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab.
The study will be done as follows:
* The last visit of parent study 230LE301 will be the first visit of study 230LE305.
* All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug.
* Globally, the treatment period will last up to 208 weeks, or 4 years. Participants will have up to 53 study visits during this time.

Start Date03 Oct 2023

Sponsor / Collaborator

Biogen, Inc.

NCT05531565

/ Active, not recruitingPhase 2/3

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms and signs of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
The main questions researchers want to answer are:
* How many participants have a score of 0 or 1 on the CLA-IGA-R looking at skin redness after treatment?
* How many participants have their skin disease activity go down by at least 70% as measured by CLASI?
Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and CLE have on the quality of life of participants using a group of questionnaires.
The study will be split into 2 parts - Part A and Part B. Both parts will be done as follows:
* After screening, participants will be randomized to receive either litifilimab or placebo for the 1st treatment period. A placebo looks like the study drug but contains no real medicine.
* Participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks.
* The 1st treatment period will be double blinded which means neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo.
* This double blinded treatment period will last 24 weeks, after which the 2nd treatment period will begin.
* During the 2nd treatment period, all participants will receive litifilimab for 28 weeks.
* After completing treatment in this study, participants that qualify will be given the choice to join the Long-Term Extension study, 230LE305. If they do not, they will move into a follow-up safety period that will last up to 24 weeks.
* The total study duration for participants will be up to 80 weeks.

Start Date13 Sep 2022

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Litifilimab

100 Translational Medicine associated with Litifilimab

100 Patents (Medical) associated with Litifilimab

Literatures (Medical) associated with Litifilimab

01 Oct 2026·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST

Article

Author: Chong, Benjamin F ; Chasset, Francois ; Carroll, Hua ; Pournara, Effie ; Yang, Weihong ; Morand, Eric F ; Werth, Victoria P ; Schindelar, Michael ; Merola, Joseph F ; Fivenson, David ; Nyberg, Filippa ; Li, Qianyun

BACKGROUND:

Cutaneous lupus erythematosus (CLE) is a serious autoimmune disease with no approved targeted treatments.

OBJECTIVE:

Evaluate the efficacy and safety of litifilimab in AMETHYST Part A (Phase 2).

METHODS:

AMETHYST is a randomized, double-blind, placebo-controlled, Phase 2/3 study that investigates litifilimab in participants with CLE. Participants were randomized to receive litifilimab 225 mg or placebo every 4 weeks during Weeks 0-24. The primary endpoint was the Cutaneous Lupus Activity Investigator's Global Assessment-Revised (CLA-IGA-R) erythema score of 0-1 at Week 16, with several Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-based endpoints at Week 24 as secondary endpoints. Safety was also assessed.

RESULTS:

Significantly more participants treated with litifilimab achieved clear/almost clear skin (CLA-IGA-R erythema 0-1) than those treated with placebo at Week 16 (14.7% vs 2.9%, P= .0263). Additionally, more participants treated with litifilimab achieved CLASI-70 response vs placebo at Week 24 (21.7% vs 5.8%, P = .0195). Litifilimab was generally well tolerated; safety data were consistent with prior studies.

LIMITATIONS:

Study was not powered to detect statistically significant differences in secondary endpoints.

CONCLUSION:

Litifilimab treatment led to greater improvements in skin disease activity vs placebo and was well tolerated in participants with CLE through Week 24.

01 Oct 2026·JOURNAL OF INTERNAL MEDICINE

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Review

Author: van Vollenhoven, Ronald

Abstract:

Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides. However, a major change in this situation is currently taking place. Over the past few years, several new biological therapeutics have been approved for the treatment of SLE (belimumab and anifrolumab) or specifically for its renal organ manifestation (obinutuzumab), along with one new small molecular treatment for the latter (voclosporin). Several additional biologicals (litifilimab and dapirolizumab) and small molecules (deucravacitinib, upadacitinib, and cerenimod) are in late‐stage clinical development. Moreover, multiple case series and case reports have been published in the past years demonstrating excellent individual results following treatments aimed at fully depleting B lymphocytes using chimeric antigen receptor bearing T cells (CAR‐T cells) or bi‐specific T‐cell engagers. These reports have raised hopes that not only solid disease control, but also a more profound state of immunological reset—deep remission—can be attained in at least some patients. In this narrative review, these developments will be described, emphasizing both the promises and the challenges they bring about, leading into some predictions of where they may lead to. A reasonable expectation is that in the coming 1–2 years, several additional biologicals and small‐molecular agents will be approved for the treatment of lupus. The most important conclusion is that the future for our patients with lupus looks brighter than ever before.

01 Oct 2026·Dermatology and Therapy

Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review

Review

Author: Jonnalagadda, Anshu ; Yildiz-Altay, Ummuguslum ; Vesely, Matthew D ; Pathak, Gaurav N ; Richmond, Rhys L ; Gehlhausen, Jeffrey R ; Desai, Amar D

BACKGROUND:

Discoid lupus erythematosus (DLE) is the most common chronic form of cutaneous lupus erythematosus and can lead to scarring, dyspigmentation, and permanent alopecia. The disease often causes visible disfigurement and has a substantial psychosocial impact. Although many patients respond to standard treatment, a subset continues to experience persistent or relapsing disease that remains difficult to control.

METHODS:

A focused literature search was performed using PubMed, Google Scholar, Web of Science, and Scopus to identify English-language studies published from January 1990 through October 2025. Search terms included "discoid lupus erythematosus," "cutaneous lupus erythematosus," "chronic cutaneous lupus," "pathogenesis," "therapy," "antimalarial," "immunosuppressant," "biologic therapy," "JAK inhibitor," "small molecule therapy," and "targeted therapy." Recent clinical trials, consensus guidelines, and review articles were prioritized. Reference lists of key publications were manually screened to capture additional relevant studies.

RESULTS:

Current first-line topical pharmacotherapeutic treatment options of DLE include photoprotection, topical corticosteroids, and calcineurin inhibitors for localized disease, and antimalarial therapy as a first-line systemic treatment. For refractory disease, systemic immunosuppressants remain common second-line options. Emerging therapies targeting interferon and cytokine signaling pathways, including anifrolumab, belimumab, and tyrosine kinase (TYK2) inhibitors such as deucravacitinib and the plasmacytoid dendritic cell modulators litifilimab and daxdilimab have shown early promise in improving cutaneous disease activity in patients with refractory DLE. Procedural modalities such as laser therapy are being studied as adjuncts for scarring and dyspigmentation.

CONCLUSIONS:

Ongoing advances in understanding the immune mechanisms underlying DLE are shaping a transition from broad immunosuppression toward more targeted treatment strategies. Integrating newer biologic and small-molecule therapies with conventional management may offer improved control and better long-term outcomes for patients with chronic disease.

News (Medical) associated with Litifilimab

28 Oct 2026

·firstwordpharma.com

CEO says Biogen has 'returned to growth' as newer drugs, Apellis drive Q3 beat

Biogen said Wednesday that third-quarter revenues rose 11% year-over-year to $2.8 billion, beating analyst expectations of $2.6 billion, as its newer medicines, including those added through its $5.6-billion acquisition of Apellis Pharmaceuticals, helped offset declines in its legacy multiple sclerosis (MS) business."Our third-quarter results demonstrate that Biogen has returned to growth," stated CEO Chris Viehbacher. Seven of eight products in the pharma's growth portfolio grew by double digits, including spinal muscular atrophy drug Spinraza (nusinersen), which saw sales jump 23% to $461 million thanks to more patients converting to the high-dose regimen. Analysts were projecting $400 million.IQLIK outpacing IV launchRevenue for Eisai-partnered Alzheimer's treatment Leqembi increased 67% to $202 million – the Japanese drugmaker records global in-market sales of the drug – with $107 million of that in the US. The global figure edged past estimates of $199 million.Moreover, the Leqembi IQLIK subcutaneous formulation – approved for maintenance dosing last year and more recently as an at-home starting dose – has been outpacing Leqembi's original intravenous (IV) launch "by three and a half and [Eli Lilly's] Kisunla by six times," according to Alisha Alaimo, who heads Biogen North America operations, though she cautioned it was still early days.Alaimo noted that while the majority of IQLIK use comes from Leqembi IV prescription writers, Biogen is "now seeing writers who have never written an [anti-amyloid therapy] before, never wrote Kisunla, never wrote [Leqembi IV]. They're writing IQLIK – and we are also seeing physicians who have only ever written Kisunla write IQLIK." She called that "a dynamic change," especially in areas with long drive times, citing the West Coast as the fastest uptake given its geography and the "convenience factor."Apellis momentumMeanwhile, Biogen also reported the first full-quarter of sales for geographic atrophy treatment Syfovre and complement inhibitor Empaveli since the Apellis deal closed in May. Syfovre generated $191 million and Empaveli $52 million, for respective gains of 27% and 92% year-over-year."I think we've really realised a synergy between the folks from Apellis who've joined the Biogen teams," said Viehbacher on an analyst call Wednesday. "They've come together and when I look at Syfovre and Empaveli you can see 37% year-over-year growth of $243 million, that's already on a run rate of $1 billion."Overall, Biogen said the growth portfolio accounted for roughly two-thirds of its core pharmaceutical revenue. MS drug sales fell 13% in the quarter to $919 million.The company is keeping its full-year outlook for mid-single-digit revenue growth in 2026, but raised the lower end of its full-year adjusted earnings guidance by 20 cents, which now falls between $12.20 and $13 per share.Five key readoutsViehbacher also highlighted early-stage work as now being one of Biogen's key priorities, calling it "one of the most important and often most neglected areas of our industry." He admitted "we were not necessarily very good with that" — the company had gone three years without a single IND – but he says there has been "a radical overhaul of the whole research and early development area."The ambition is to have at least 20 programmes in early-stage development over the next few years. "This is a big shift in how we operate because Biogen historically has looked at things on an asset-by-asset basis," Viehbacher said.The company has five registrational study readouts on the horizon over the next year. Two Phase III trials of litifilimab, a IgG1 monoclonal antibody, are due in systemic lupus by year-end, with a third in cutaneous lupus to follow in the first half of 2027. That same half-year should also bring results from a Phase III study of felzartamab, a CD38-targeting antibody in development for antibody-mediated rejection (AMR) in kidney transplant recipients.Phase III results for zorevunersen, an antisense oligonucleotide it is co-developing with Stoke Therapeutics to treat Dravet syndrome, are expected towards the end of next year.

AcquisitionPhase 3Drug ApprovalClinical ResultOligonucleotide

28 Oct 2026

·www.biospace.com

Biogen set up for growth even without M&A but CEO won’t rule it out

iStock, Yutthana Gaetgeaw Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO Chris Viehbacher said on a Q3 earnings call Wednesday. After three straight quarters of rising revenue thanks to existing products, Biogen now sees its carefully crafted late-stage pipeline as icing on the cake, with deals another nice to have but not necessary sprinkle on top. “Given the Apellis acquisition, we now think that the company can grow even without the pipeline,” CEO Chris Viehbacher said on a Wednesday morning earnings call. “So as the pipeline starts to read out . . . we’ll be able to launch products on top of a growing base.” Growth was certainly the topic du jour during Biogen’s third-quarter earnings report—with some variation of the word spoken 48 times on the call by the company executives or analysts eager to understand their strategy. That growth was generated by increasing sales of Alzheimer’s disease therapy Leqembi and spinal muscular atrophy antisense oligonucleotide Spinraza, as well as the products Biogen acquired in its $5.6 billion Apellis Pharmaceuticals buy in March. Earnings Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis Growth portfolio products like Leqembi and Spinraza helped drive Biogen to $2.8 billion in revenue for the third quarter. October 28, 2026 · 1 min read · Annalee Armstrong Read more Now, the company is looking to three key pipeline products: litifilimab in two types of lupus, felzartamab in antibody-mediated rejection (AMR) and zorevunersen for Dravet syndrome. Biogen has key registrational readouts for litifilimab coming in the next four quarters: Two Phase 3 readouts in systemic lupus erythematosus are expected first, by the end of this year, followed by a late-stage readout in cutaneous lupus erythematosus in the first half of 2027. With these trials poised to deliver data that could launch meaningful products, Viehbacher said the company will stay focused on developing internal programs while watching for potential early-stage business development opportunities. “Investors have waited a long time for us to grow, and so we’re going to be very mindful of different ratios and the amount of investment versus growing our bottom line,” the CEO said. “But I think we can manage all of that actually.” Apellis was a late-stage addition, adding two approved medicines in kidney and eye disease. Viehbacher reiterated his preference for earlier-stage acquisitions going forward. “I’ve really always hated having to go buy assets in later stage because there’s still a fair amount of risk associated with that,” Viehbacher said. “If we have reasonable success with the pipeline—again we have to wait and see the results—but there’s a good potential that the company can just grow now for the foreseeable future.” Viehbacher said that assets in the discovery stage to Phase 1b that can fit into Biogen’s existing franchises are the company’s “sweet spot” as they have become more opportunistic than intentional about deals. “One of the things I’m quite mindful of is distraction. We have dramatically changed at Biogen,” Viehbacher said. While just a few years ago the company was pitching its therapies solely to neurologists, Biogen’s commercial teams are now working with nephrologists, dermatologists, retina specialists and rheumatologists across the product portfolio. “All of that is a tremendous amount of change, and I think we really want to be able to digest that change and really take advantage of the opportunities that are in front of us and be careful about overextending ourselves,” the CEO said. Mergers & acquisitions Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials. March 31, 2026 · 4 min read · Annalee Armstrong Read more

AcquisitionPhase 3Oligonucleotide

08 Oct 2026

·pmlive.com

Biogen announces phase 2 data for cutaneous lupus erythematosus

Biogen has announced 52-week results from the phase 2 part of the ongoing AMETHYST phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest data set reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks. “People living with cutaneous lupus erythematosus face debilitating symptoms, including scarring, hair loss and extreme sensitivity to light, yet they have long relied on treatments not specifically developed or studied for CLE,” said Albert T Roy, President and CEO of the Lupus Research Alliance. “The new data on litifilimab is encouraging because it points to the potential for both rapid symptom relief and durable improvement for people living with this condition.” Litifilimab is being evaluated as a potential once-monthly, first-in-class treatment designed to reduce inflammation at its source by selectively targeting blood dendritic cell antigen 2 (BDCA2) receptors on plasmacytoid dendritic cells (pDCs), which play a central role early in the inflammatory process in CLE. In January 2026, litifilimab was granted Breakthrough Therapy Designation by the US FDA for the treatment of CLE. “Living with cutaneous lupus erythematosus carries a heavy physical toll, including dyspigmentation, pain, and scarring, which can be associated with comorbidities like depression and anxiety that can have a profound impact on daily life. The 52-week data reinforce litifilimab’s potential to deliver rapid improvement and demonstrate its durable skin clearance effects,” said Daniel Quirk, Chief Medical Officer at Biogen.

Clinical ResultPhase 2Breakthrough Therapy

100 Deals associated with Litifilimab

External Link

KEGG	Wiki	ATC	Drug Bank
D12232	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lupus Erythematosus, Cutaneous	Phase 3	United States	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	China	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Japan	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Argentina	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Belgium	Biogen Idec Research Ltd.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Brazil	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Bulgaria	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Canada	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Chile	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Colombia	Biogen, Inc.	03 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05531565 (AMETHYST, ACR2026)	Phase 2/3	Lupus Erythematosus, Cutaneous	93	Litifilimab	gtiitiveik(ycpijgzxpo) = vhvwqoguce zuruhfjxvz (gaktviurpg ) View more	Positive	06 Nov 2026
				Placebo	magefojhql(kikmrzfcok) = ajphwwxlfv lwnknxkhlz (oerdpapnzg ) View more
NCT02847598 (LILAC \| LILAC study, CTgov)	Phase 2	Lupus Erythematosus, Cutaneous \| Systemic Lupus Erythematosus \| Lupus Erythematosus, Discoid	264	Placebo (Part A: Placebo)	edeqtbvsjk(hqrvpfpvgx) = xwggsmjapw duuhumhiig (amcmbopblh, 10.3) View more	-	15 May 2023
				BIIB059 (litifilimab) (Part A: BIIB059 450 mg)	edeqtbvsjk(hqrvpfpvgx) = hwzpndnonb duuhumhiig (amcmbopblh, 8.7) View more
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Systemic Lupus Erythematosus BDCA2	132	Litifilimab 450 mg	alqneyzway(wrjmmfuban): P-Value = 0.04 View more	Positive	08 Sep 2022
				Placebo
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Lupus Erythematosus, Cutaneous	132	Litifilimab 50 mg	pajxtauoas(xqqvicexjx) = Litifilimab was associated with one case of herpes zoster infection csucvtksll (sdijujfase ) View more	Positive	28 Jul 2022
				Litifilimab 150 mg
NCT02847598 (LILAC study, EULAR2022)	Phase 2	Lupus Erythematosus, Cutaneous BDCA2	-	BIIB059	wdxbaoeqbm(odgmzouyhq) = rzkcjybxgd icfaltfbrk (ovqbkzznpn ) View more	Positive	01 Jun 2022
NCT02847598 (LILAC, EULAR2022)	Phase 2	Systemic Lupus Erythematosus anti-nuclear antibodies \| anti-double-stranded DNA antibodies	-	BIIB059 450 mg	bkoqnglevy(jxjycepvoc) = fabjmyjghz trmzcnzjrj (dwozsxlnob ) View more	Positive	01 Jun 2022
				Placebo	bkoqnglevy(jxjycepvoc) = ylyeynzqbo trmzcnzjrj (dwozsxlnob ) View more
NCT02847598 (LILAC, ACR2020) Manual	Phase 2	Systemic Lupus Erythematosus	120	BIIB059	hkiflzetsk(cwudvskedd) = kdwiiuxpum kneftjevff (mywlnixmmh, 1.2) View more	Positive	07 Nov 2020
				Placebo	hkiflzetsk(cwudvskedd) = akbdvqjpct kneftjevff (mywlnixmmh, 1.3) View more
NCT02847598 (LILAC, EULAR2020)	Phase 2	Lupus Erythematosus, Cutaneous	132	BIIB059 50 mg	epgvhumwfq(yeoqlmzgye) = 62 (62.6%) 80 (60.6%) zvgejlxbkb (umjmfnfhlq ) View more	Positive	03 Jun 2020
				BIIB059 150 mg
NCT02847598 (Pubmed \| J Pharmacokinet Pharmacodyn)	Phase 2	Lupus Erythematosus, Cutaneous	264	BIIB059	aicbqwtxkl(gxgoqedase) = wzoiunopfr ygahaczyau (hwvaiaxbjt ) View more	-	01 Jun 2020
NCT02106897 (Pubmed \| J Clin Invest) Manual	Phase 1	Eczema \| Systemic Lupus Erythematosus	54	BIIB059	sedhyngjgi(jawstfidnk) = oiqslbfckd povakfnlah (mqwnpovuuq ) View more	Positive	01 Mar 2019
				Placebo	sedhyngjgi(jawstfidnk) = btpotgmdvv povakfnlah (mqwnpovuuq ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis